Inactive Instrument

F-star Therapeutics, Inc.

Equities

FSTX

US30315R1077

Biotechnology & Medical Research

F-star Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

November 10, 2022 at 04:32 pm EST

F-star Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 1.13 million compared to USD 0.751 million a year ago. Net loss was USD 18.41 million compared to USD 10.79 million a year ago. Basic loss per share from continuing operations was USD 0.84 compared to USD 0.52 a year ago.
For the nine months, sales was USD 3.68 million compared to USD 3.67 million a year ago. Net loss was USD 49.49 million compared to USD 36.02 million a year ago. Basic loss per share from continuing operations was USD 2.3 compared to USD 2.35 a year ago.

Latest news about F-star Therapeutics, Inc.

F-star Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-09-28	CI
F-Star Entered into Strategic Collaboration and Licence Agreement with Takeda to Discover and Develop Next-Generationmulti-Specific Antibodies	23-07-05	CI
F-Star Announces Licence Agreement with Takeda for Second Novel Next-Generation Immuno-Oncology Bispecific Antibody	23-03-22	CI
F-star Therapeutics, Inc.(NasdaqCM:FSTX) dropped from S&P TMI Index	23-03-10	CI
F-star Therapeutics, Inc.(NasdaqCM:FSTX) dropped from S&P Global BMI Index	23-03-10	CI
F-star Therapeutics Gets Acquired by invoX Pharma for $161 Million	23-03-09	MT
F-star Therapeutics, Inc.(NasdaqCM:FSTX) dropped from NASDAQ Composite Index	23-03-09	CI
Sino Biopharmaceutical Completes $161 Million Acquisition of F-star Therapeutics	23-03-08	MT
InvoX Pharma Limited completed the acquisition of F-star Therapeutics, Inc.	23-03-07	CI
F-star Therapeutics Gets Final Regulatory Nod For Acquisition by Invox Pharma	23-03-07	MT
F-star Therapeutics Shares Rally After Cfius Clears Takeover	23-03-07	DJ
Top Midday Gainers	22-12-30	MT
F-Star Therapeutics Shares Erase Much of Thursday's Loss	22-12-30	DJ
F-star Therapeutics Extends invoX Deal Date to Help Address CFIUS Concerns; Shares Rise	22-12-30	MT
F-star Therapeutics Says US Regulator Blocks Merger With invoX Pharma on National Security Concern; Shares Slump	22-12-29	MT
Top Premarket Gainers	22-12-21	MT
F-star Therapeutics, Inc. Presents Clinical Data on FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, at ESMO-IO 2022 Congress	22-12-06	CI
Sector Update: Health Care Stocks Advance Modestly	22-11-21	MT
Sector Update: Health Care	22-11-21	MT
F-star Therapeutics, invoX Pharma Extend Merger Completion Date	22-11-21	MT
F-star Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
F-star Therapeutics, Inc. Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research	22-11-07	CI
Top Premarket Decliners	22-10-28	MT
US Stock Futures Lower Ahead of Consumer Sentiment, Pending Home Sales Data	22-10-28	MT
F-star Therapeutics, Inc.(NasdaqCM:FSTX) added to S&P Global BMI Index	22-09-19	CI

Chart F-star Therapeutics, Inc.

Duration

Period

More charts

Company Profile

F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing immunotherapies to transform the lives of patients with cancer. The Company's FS118 is the lead product candidate, which is in Phase II trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing FS222, FS120 and SB 11285 in Phase I clinical trials in patients with advanced cancers. FS222 is focused on patients with tumors that express low levels of PD-L1 and is a tetravalent, bispecific natural antibody (mAb2) bispecific antibody that is designed to target both the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. FS120 is focused to improve checkpoint inhibitor and chemotherapy outcomes and is a mAb2 bispecific antibody that is designed to bind to and stimulate OX40 and CD137. Its product candidate SB 11285 is focused on improving checkpoint inhibition outcomes as an immunotherapeutic compound for the treatment of selected cancers.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	102B
REGENERON PHARMACEUTICALS, INC.	+1.62%	96.29B
ARGENX SE	+1.46%	22.18B
BIONTECH SE	-16.67%	21.2B
GENMAB A/S	-8.58%	18.31B
WUXI APPTEC CO., LTD.	-38.74%	17.38B
BEIGENE, LTD.	-13.21%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.97B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs